



Model List of Essential Medicines



Abiraterone [General information](#)

Section

Hormones and antihormones

- Oral > Solid: 250 mg; 500 mg

Indications

[Malignant neoplasms of prostate](#)



Aclidinium [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for [Chronic obstructive pulmonary disease](#)



Adalimumab [General information](#)

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

[Axial spondyloarthritis](#) [Crohn disease site](#) [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

[Juvenile idiopathic arthritis](#)



Afatinib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) for [Other specified malignant neoplasms of bronchus or lung](#)



Alteplase [General information](#)

Section

Thrombolytic medicines

- Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50

mg in vial powder for injection

Indications

[Cerebral ischaemic stroke](#)



Amodiaquine - sulfadoxine + pyrimethamine [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package

Indications

[Malaria](#)



Amoxicillin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

Indications

First choice

[Periapical abscess without sinus](#)



Amoxicillin + clavulanic acid [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

Second choice

[Other specified prophylactic measures](#)

Section

Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Apixaban [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#) for [Venous thromboembolism](#)



Aprepitant [General information](#)

Section

Antiemetic medicines

- Oral > Liquid: 125 mg powder for oral suspension (in sachet)

- Oral > Solid > capsule: 80 mg; 125 mg; 165 mg

Indications

[Nausea or vomiting](#)

Arsenic trioxide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#)

Azithromycin [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

[Paratyphoid fever](#) [Typhoid fever](#)

Bortezomib [General information](#)

Section

Targeted therapies

- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

Indications

[Plasma cell myeloma](#)

Carbetocin [General information](#)

Section

Uterotonics

- Parenteral > General injections > IV: 100 µg per mL (heat stable)

Indications

[Postpartum haemorrhage](#)

Carbimazole [General information](#)

Section

Thyroid hormones and antithyroid medicines

Indications

Therapeutic equivalent to [methimazole](#) for [Thyrotoxicosis](#)

Carboplatin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

[Malignant neoplasms of cervix uteri](#)

Cefazolin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

First choice

[Other specified prophylactic measures](#) [Other specified prophylactic measures](#)

Ceftazidime + avibactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Ceftriaxone [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

[Paratyphoid fever](#) [Typhoid fever](#)

Cefuroxime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

[Other specified prophylactic measures](#)

Certolizumab pegol [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)

Ciprofloxacin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

Indications

First choice

[Paratyphoid fever](#) [Typhoid fever](#)

Colistin (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

[Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)

Cyclophosphamide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg

Indications

[Plasma cell myeloma](#)

Dabigatran [General information](#)

Section

Medicines affecting coagulation

- Oral > Solid: 110 mg; 150 mg

Indications

[Other specified atrial fibrillation Venous thromboembolism](#)

Dengue vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)

Dexamethasone [General information](#)

Section

Hormones and antihormones

- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 4 mg (as dexamethasone base)

Indications

[Plasma cell myeloma](#)

Diazoxide [General information](#)

Section

Medicines for hypoglycaemia

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 50 mg

Indications

[Persistent hyperinsulinaemic hypoglycaemia of infancy](#)

Dolutegravir + lamivudine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Doxorubicin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

[Plasma cell myeloma](#)

Edoxaban [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#) for [Venous thromboembolism](#)

Enzalutamide [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [abiraterone](#) for [Malignant neoplasms of prostate](#)

Erlotinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 100 mg; 150 mg

Indications

[Other specified malignant neoplasms of bronchus or lung](#)

Etanercept [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)

Fexinidazole [General information](#)

Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Oral > Solid: 600 mg

Indications

[Gambiense trypanosomiasis](#)

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Oral > Solid: 600 mg

Indications

[Gambiense trypanosomiasis](#)

Fosfomycin (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

[Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Gefitinib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) for [Other specified malignant neoplasms of bronchus or lung](#)

Gentamicin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

Second choice

[Other specified prophylactic measures](#)

Glecaprevir + pibrentasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg

Indications

[Chronic hepatitis C](#)

Glycopyrronium [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for [Chronic obstructive pulmonary disease](#)

Golimumab [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)

Imipenem + cilastatin [General information](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [meropenem](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

Infliximab [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)

Ivermectin [General information](#)

Section

Medicines for ectoparasitic infections

- Oral > Solid > tablet: 3 mg

Indications

[Scabies](#)



Lenalidomide [General information](#)

Section

Immunomodulators

- Oral > Solid: 25 mg

Indications

[Plasma cell myeloma](#)



Linezolid [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg

Indications

[Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus](#)



Lisinopril + amlodipine [General information](#)

Section

Antihypertensive medicines

- Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg

Indications

[Essential hypertension](#)



Lisinopril + hydrochlorothiazide [General information](#)

Section

Antihypertensive medicines

- Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg

Indications

[Essential hypertension](#)



Melphalan [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg

Indications

[Plasma cell myeloma](#)



Meropenem [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Meropenem + vaborbactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii](#)

Methimazole [General information](#)

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid > tablet: 5 mg; 10 mg

Indications

[Thyrotoxicosis](#)

Metronidazole [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Indications

First choice

co-prescribed with [cefazolin Other specified prophylactic measures](#)

Multiple micronutrient powder [General information](#)

Section

Vitamins and minerals

- Sachets containing:
 - - iron (elemental) 12.5 mg (as coated ferrous fumarate)
 - - zinc (elemental) 5 mg
 - - vitamin A 300 micrograms
 - - with or without other micronutrients at recommended daily values

Indications

[Iron deficiency anaemia](#)

Nivolumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion

Indications

[Melanoma of skin](#)

Oral rehydration salts - zinc sulfate [General information](#)

Section

Medicines used in diarrhoea

- Oral > Other: ORS powder for dilution and zinc sulfate dispersible tablet 20 mg (co-packaged)

Indications

[Diarrhoea](#)

Paclitaxel [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 6 mg per mL

Indications

[Malignant neoplasms of cervix uteri](#)

Pegaspargase [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

[Lymphoid leukaemia, not elsewhere classified](#)

Pembrolizumab [General information](#)

Section

Immunomodulators

Indications

Therapeutic equivalent to [nivolumab](#) for [Melanoma of skin](#)

Phenoxyethylpenicillin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

First choice

[Periapical abscess without sinus](#)

Plazomicin [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg per 10 mL

Indications

[Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Polymyxin B (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#) [Carbapenem resistant Acinetobacter baumannii](#)

Prednisolone [General information](#)

Section

Hormones and antihormones

- Oral > Solid: 5 mg; 25 mg

Indications

[Plasma cell myeloma](#) [Malignant neoplasms of prostate](#)

Prednisone [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [prednisolone](#) for [Plasma cell myeloma](#) Therapeutic equivalent to [prednisolone](#) for [Malignant neoplasms of prostate](#)

Procarbazine [General information](#)

Section

Cytotoxic medicines

- Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

[Hodgkin lymphoma](#)

Realgar-indigo naturalis formulation [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#)

Rivaroxaban [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#) for [Venous thromboembolism](#)

Sulfadoxine + pyrimethamine [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 500 mg + 25 mg tablet
- Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria](#)

Tedizolid [General information](#)

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to [linezolid](#) for [Methicillin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Enterococcus](#)

Telmisartan + amlodipine [General information](#)

Section

Antihypertensive medicines

- Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg

Indications

[Essential hypertension](#)

Telmisartan + hydrochlorothiazide [General information](#)

Section

Antihypertensive medicines

- Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg

Indications

[Essential hypertension](#)

Thalidomide [General information](#)

Section

Immunomodulators

- Oral > Solid: 50 mg

Indications

[Plasma cell myeloma](#)

Tiotropium bromide [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Respiratory > Inhalation > powder: 18 µg in capsule

- Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler; 2.5 µg per actuation in soft mist inhaler

Indications

[Chronic obstructive pulmonary disease](#)

Tranexamic acid [General information](#)

Section

Other medicines administered to the mother

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

[Postpartum haemorrhage](#)

Umeclidinium [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for [Chronic obstructive pulmonary disease](#)